185 related articles for article (PubMed ID: 2558243)
21. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
22. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
23. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
24. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
25. Clinical use of gynaecologic tumour markers.
Halila H; Alfthan H; Stenman UH
Ann Chir Gynaecol; 1989; 78(1):65-70. PubMed ID: 2547331
[TBL] [Abstract][Full Text] [Related]
26. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
27. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
Menczer J; Ben-Baruch G; Moran O; Lipitz S
Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
[TBL] [Abstract][Full Text] [Related]
28. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
29. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
30. CA54/61 as a marker for epithelial ovarian cancer.
Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
[TBL] [Abstract][Full Text] [Related]
31. [Biomarker in gynecologic malignancies].
Isonishi S
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors].
Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
Rinsho Byori; 1985 Feb; 33(2):173-7. PubMed ID: 3858562
[No Abstract] [Full Text] [Related]
34. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.
Høgdall CK; Mogensen O; Tabor A; Mogensen B; Jakobsen AK; Nørgaard-Pedersen B; Larsen SO; Clemmensen I
Gynecol Oncol; 1995 Jan; 56(1):22-8. PubMed ID: 7821842
[TBL] [Abstract][Full Text] [Related]
35. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
36. [New technology of diagnosis of ovarian cancer].
Terashima Y
Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
[TBL] [Abstract][Full Text] [Related]
37. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
38. Telomerase activity as a biological marker in some gynecological tumors: comparison with tissue and serum CA 125.
Novakovic S; Fras PA; Jezersek-Novakovic B
In Vivo; 2001; 15(4):327-32. PubMed ID: 11695225
[TBL] [Abstract][Full Text] [Related]
39. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]